{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:17:52Z","timestamp":1791958672937,"version":"4.3.4"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Upper and lower limb spasticity (ULS, LLS) often occur following a stroke or in patients with other neurological disorders, leading to difficulties in mobility and daily living and decreased quality of life. Prior to the use of onabotulinumtoxinA, antispastic medications had limited efficacy and often caused sedation. Phenol injections were difficult for physicians to perform, painful, and led to tissue destruction. The success of onabotulinumtoxinA in treating cervical dystonia led to its use in spasticity. However, many challenges characterized the development of onabotulinumtoxinA for adult spasticity. The wide variability in the presentation of spasticity among patients rendered it difficult to determine which muscles to inject and how to measure improvement. Another challenge was the initial refusal of the Food and Drug Administration to accept the Ashworth Scale as a primary endpoint. Additional scales were designed to incorporate a goal-oriented, patient-centered approach that also accounted for the variability of spasticity presentations. Several randomized, double-blind, placebo-controlled trials of post-stroke spasticity of the elbow, wrist, and\/or fingers showed significantly greater improvements in the modified Ashworth Scale and patient treatment goals and led to the approval of onabotulinumtoxinA for the treatment of ULS in adult patients. Lessons learned from the successful ULS trials were applied to design an LLS trial that led to approval for the latter indication. Additional observational trials mimicking real-world treatment have shown continued effectiveness and patient satisfaction. The use of onabotulinumtoxinA for spasticity has ushered in a more patient-centered treatment approach that has vastly improved patients\u2019 quality of life.<\/jats:p>","DOI":"10.1097\/md.0000000000032376","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:01:34Z","timestamp":1690484494000},"page":"e32376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Alberto","family":"Esquenazi","sequence":"first","affiliation":[{"name":"MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Freiburg, Freiburg, Germany, and Parkinson-Hospital Ortenau, Wolfach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Turkel","sequence":"additional","affiliation":[{"name":"Novus Therapeutics, Inc., Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Wein","sequence":"additional","affiliation":[{"name":"Department of Neurology, McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie Company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/STROKEAHA.110.581991","article-title":"Occurence and clinical predictors of spasticity after ischemic stroke.","volume":"41","author":"Urban","year":"2010","journal-title":"Stroke"},{"issue":"3 Suppl 2","key":"R3-20240803","first-page":"S13","article-title":"Toward an epidemiology of poststroke spasticity.","volume":"80","author":"Wissel","year":"2013","journal-title":"Neurology"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients.","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult Scler"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00001199-199808000-00005","article-title":"Undiagnosed health issues in individuals with traumatic brain injury living in the community.","volume":"13","author":"Hibbard","year":"1998","journal-title":"J Head Trauma Rehabil"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/S0003-9993(99)90329-5","article-title":"Spasticity after traumatic spinal cord injury: nature, severity, and location.","volume":"80","author":"Sk\u00f6ld","year":"1999","journal-title":"Arch Phys Med Rehabil"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1469-8749.2001.tb00719.x","article-title":"Adults with cerebral palsy: a survey describing problems, needs, and resources, with special emphasis on locomotion.","volume":"43","author":"Andersson","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12955-015-0340-3","article-title":"The negative impact of spasticity on the health-related quality of life of stroke survivors: a longitudinal cohort study.","volume":"13","author":"Gillard","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00415-010-5463-1","article-title":"Early development of spasticity following stroke: a prospective, observational trial.","volume":"257","author":"Wissel","year":"2010","journal-title":"J Neurol"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/09638280500535165","article-title":"Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study.","volume":"28","author":"Ada","year":"2006","journal-title":"Disabil Rehabil"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/ijtr.2007.14.9.24579","article-title":"What is spasticity? The discussion continues.","volume":"14","author":"Ibuki","year":"2007","journal-title":"Int J Ther Rehabil"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/jnnp.56.5.531","article-title":"The limitations of the tendon jerk as a marker of pathological stretch reflex activity in human spasticity.","volume":"56","author":"Fellows","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 5","key":"R14-20240803","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/brain\/119.5.1737","article-title":"Spasticity and muscle contracture following stroke.","volume":"119","author":"O\u2019Dwyer","year":"1996","journal-title":"Brain"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.410300605","article-title":"Reflex activity and muscle tone during elbow movements in patients with spastic paresis.","volume":"30","author":"Dietz","year":"1991","journal-title":"Ann Neurol"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/(SICI)1097-4598(1997)6+<92::AID-MUS7>3.0.CO;2-E","article-title":"Traditional pharmacological treatments for spasticity. Part II: general and regional treatments.","volume":"6","author":"Gracies","year":"1997","journal-title":"Muscle Nerve Suppl"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/(SICI)1097-4598(1997)6+<61::AID-MUS6>3.0.CO;2-H","article-title":"Traditional pharmacological treatments for spasticity. Part I: local treatments.","volume":"6","author":"Gracies","year":"1997","journal-title":"Muscle Nerve Suppl"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4103\/JPN.JPN_123_17","article-title":"Phenol versus botulinum toxin A injection in ambulatory cerebral palsy spastic diplegia: a comparative study.","volume":"12","author":"Gonnade","year":"2017","journal-title":"J Pediatr Neurosci"},{"key":"R19-20240803","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1469-8749.1988.tb04720.x","article-title":"For how long must the soleus muscle be stretched each day to prevent contracture?","volume":"30","author":"Tardieu","year":"1988","journal-title":"Dev Med Child Neurol"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archopht.1984.01040031184014","article-title":"Treatment of blepharospasm with botulinum toxin. A preliminary report.","volume":"102","author":"Frueh","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S031716710003540X","article-title":"A pilot study on the use of botulinum toxin in spasmodic torticollis.","volume":"12","author":"Tsui","year":"1985","journal-title":"Can J Neurol Sci"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0733-8635(03)00019-6","article-title":"Development of botulinum toxin therapy.","volume":"22","author":"Scott","year":"2004","journal-title":"Dermatol Clin"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.410280407","article-title":"Treatment of spasticity with botulinum toxin: a double-blind study.","volume":"28","author":"Snow","year":"1990","journal-title":"Ann Neurol"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.46.5.1306","article-title":"Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.","volume":"46","author":"Simpson","year":"1996","journal-title":"Neurology"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/(SICI)1097-4598(1997)6+<21::AID-MUS4>3.0.CO;2-L","article-title":"Common patterns of clinical motor dysfunction.","volume":"6","author":"Mayer","year":"1997","journal-title":"Muscle Nerve Suppl"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/PHM.0000000000001101","article-title":"Optimal muscle selection for onabotulinumtoxinA injections in poststroke lower-limb spasticity: a randomized trial.","volume":"98","author":"Esquenazi","year":"2019","journal-title":"Am J Phys Med Rehabil"},{"key":"R29-20240803","first-page":"540","article-title":"Preliminary trial of carisoprodol in multiple sclerosis.","volume":"192","author":"Ashworth","year":"1964","journal-title":"Practitioner"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","article-title":"Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke.","volume":"85","author":"Childers","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1053\/apmr.2002.35474","article-title":"Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity.","volume":"83","author":"Brashear","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.pmrj.2017.12.006","article-title":"OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: a randomized trial.","volume":"10","author":"Wein","year":"2018","journal-title":"PM R"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology.","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"R35-20240803","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2340\/16501977-2226","article-title":"Assessment and treatment of spastic equinovarus foot after stroke: guidance from the Mont-Godinne interdisciplinary group.","volume":"49","author":"Deltombe","year":"2017","journal-title":"J Rehabil Med"},{"key":"R37-20240803","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/STR.0000000000000098","article-title":"Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"47","author":"Winstein","year":"2016","journal-title":"Stroke"},{"key":"R39-20240803","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa011892","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.","volume":"347","author":"Brashear","year":"2002","journal-title":"N Engl J Med"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1212\/01.WNL.0000144349.95487.91","article-title":"Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.","volume":"63","author":"Gordon","year":"2004","journal-title":"Neurology"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity.","volume":"26","author":"Kaji","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00415-010-5526-3","article-title":"Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial.","volume":"257","author":"Kaji","year":"2010","journal-title":"J Neurol"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.apmr.2009.02.026","article-title":"A preliminary assessment of the benefits of the addition of botulinum toxin A to a conventional therapy program on the function of people with longstanding stroke.","volume":"90","author":"Meythaler","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"key":"R44-20240803","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jnnp.2008.159657","article-title":"Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study.","volume":"80","author":"Simpson","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R45-20240803","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10072-005-0378-9","article-title":"A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.","volume":"26","author":"Mancini","year":"2005","journal-title":"Neurol Sci"},{"key":"R46-20240803","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ene.12381","article-title":"Early botulinum toxin treatment for spastic pes equinovarus\u2013a randomized double-blind placebo-controlled study.","volume":"21","author":"Fietzek","year":"2014","journal-title":"Eur J Neurol"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.pmrj.2018.02.011","article-title":"The effects of botulinum toxin injections on plantar flexor spasticity in different phases after stroke: a secondary analysis from a double-blind, randomized trial.","volume":"10","author":"Oh","year":"2018","journal-title":"PM R"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10072-005-0379-8","article-title":"Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.","volume":"26","author":"Slawek","year":"2005","journal-title":"Neurol Sci"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00702-020-02251-6","article-title":"Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study.","volume":"127","author":"Patel","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"R50-20240803","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2340\/16501977-1817","article-title":"Functional goal achievement in post-stroke spasticity patients: the Botox\u00ae Economic Spasticity Trial (BEST).","volume":"46","author":"Ward","year":"2014","journal-title":"J Rehabil Med"},{"key":"R51-20240803","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpainsymman.2016.01.007","article-title":"OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: findings from a randomized, double-blind, placebo-controlled trial.","volume":"52","author":"Wissel","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R52-20240803","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PHM.0b013e31824fa9ca","article-title":"Patient registry of outcomes in spasticity care.","volume":"91","author":"Esquenazi","year":"2012","journal-title":"Am J Phys Med Rehabil"},{"key":"R53-20240803","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2340\/16501977-2245","article-title":"Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics.","volume":"49","author":"Francisco","year":"2017","journal-title":"J Rehabil Med"},{"key":"R54-20240803","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.toxcx.2020.100040","article-title":"High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.","volume":"7","author":"Francisco","year":"2020","journal-title":"Toxicon X"},{"key":"R55-20240803","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pmrj.12328","article-title":"Individualized onabotulinumtoxinA treatment for upper limb spasticity resulted in high clinician- and patient-reported satisfaction: long-term observational results from the ASPIRE study.","volume":"12","author":"Francisco","year":"2020","journal-title":"PM R"},{"key":"R56-20240803","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/cjn.2016.262","article-title":"Real-world, long-term quality of life following therapeutic onabotulinumtoxinA treatment.","volume":"43","author":"Jog","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"R57-20240803","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.apmr.2006.02.015","article-title":"Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity.","volume":"87","author":"Turkel","year":"2006","journal-title":"Arch Phys Med Rehabil"},{"key":"R58-20240803","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/toxins12100661","article-title":"Safety and stability of pulmonary function in patients with decreased respiratory function treated for spasticity with onabotulinumtoxinA.","volume":"12","author":"Ayyoub","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R59-20240803","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (Botox\u00ae) across multiple indications.","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"key":"R60-20240803","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence.","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:55Z","timestamp":1722736615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":55,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032376","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}